Fig. 1: PSA Response, and Objective Response: Best Change in PSA Level and Target Lesions in Patients with mCRPC Treated with BAT and Nivolumab. | Nature Communications

Fig. 1: PSA Response, and Objective Response: Best Change in PSA Level and Target Lesions in Patients with mCRPC Treated with BAT and Nivolumab.

From: Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial

Fig. 1

A Waterfall plot showing the best PSA decline from baseline for each patient (N = 45). Eighteen (N = 18) patients were observed to have a confirmed PSA decline of 50% or greater while on treatment with BAT and nivolumab. Two additional patients achieved an unconfirmed PSA50 response denoted by *. B Waterfall plot showing best change in tumor volume for N = 42 evaluable patients with measureable disease. Ten (N = 10) patients achieved a 30% or greater decrease in target lesions while receiving study treatment. # indicates progressive disease as best response due to new lesions. Source data are available as a Source Data file.

Back to article page